Immune control of hepatitis B virus

Digestive Diseases

Volumn 29, Issue 4, 2011, Pages 423-433

  Bauer, Tanja ^a   Sprinzl, Martin ^a   Protzer, Ulrike ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adaptive immunity; Hepatitis B virus clearance; Immunopathogenesis; Innate immunity; Viral persistence

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DISEASE ASSOCIATION; FLOW CYTOMETRY; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KUPFFER CELL; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER INJURY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION; VIREMIA; VIRION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIGEN PRESENTATION; DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNITY; RECEPTORS, PATTERN RECOGNITION;

EID: 80052434179     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000329809     Document Type: Article

References (106)

1. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129. (Pubitemid 38298992)
2. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229. (Pubitemid 40364823)
3. Rouse BT, Sehrawat S: Immunity and immunopathology to viruses: What decides the outcome? Nat Rev Immunol 2010; 10: 514-526.
4. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124: 783-801. (Pubitemid 43261452)
5. Uprichard SL, Wieland SF, Althage A, Chisari FV: Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci USA 2003; 100: 1310-1315. (Pubitemid 36183998)
6. Dumortier J, Schonig K, Oberwinkler H, et al: Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther 2005; 12: 668-677. (Pubitemid 40561505)
7. Klocker U, Schultz U, Schaller H, Protzer U: Endotoxin stimulates liver macrophages to release mediators that inhibit an early step in hepadnavirus replication. J Virol 2000; 74: 5525-5533. (Pubitemid 30346585)
8. Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272. (Pubitemid 40677357)
9. McClary H, Koch R, Chisari FV, Guidotti LG: Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264. (Pubitemid 30091480)
10. Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173. (Pubitemid 30214422)
11. Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854. (Pubitemid 40327973)
12. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4:e1000017.
13. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al: Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132-1140.
14. Lucifora J, Arzberger S, Durantel D, et al: Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011, E-pub ahead of print.
15. Hosel M, Quasdorff M, Wiegmann K, et al: Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782.
16. Wieland SF, Chisari FV: Stealth and cunning: Hepatitis B and hepatitis C viruses. J Virol 2005; 79: 9369-9380. (Pubitemid 41022281)
17. Martinon F, Mayor A, Tschopp J: The inflammasomes: Guardians of the body. Annu Rev Immunol 2009; 27: 229-265.
18. Randall RE, Goodbourn S: Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89: 1-47.
19. Pollicino T, Belloni L, Raffa G, et al: Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837. (Pubitemid 43374531)
20. Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-6674. (Pubitemid 38586032)
21. Cooper A, Tal G, Lider O, Shaul Y: Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005; 175: 3165-3176. (Pubitemid 41170538)
22. Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G: Immunostimulatory potential of hepatitis B nucleocapsid preparations: Lipopolysaccharide contamination should not be overlooked. J Gen Virol 2005; 86: 323-331. (Pubitemid 40227943)
23. Arzberger S, Hosel M, Protzer U: Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus. J Virol 2010; 84: 11994-12001.
24. Riordan SM, Skinner N, Kurtovic J, Locarnini S, Visvanathan K: Reduced expression of Toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006; 13: 972-974. (Pubitemid 44409640)
25. Visvanathan K, Skinner NA, Thompson AJ, et al: Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102-110. (Pubitemid 46150869)
26. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A: The Hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol 2011, E-pub ahead of print.
27. Torre D, Zeroli C, Giola M, et al: Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin- 6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994; 18: 194-198.
28. Dunn C, Brunetto M, Reynolds G, et al: Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680. (Pubitemid 46457088)
29. Webster GJ, Reignat S, Maini MK, et al: Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-1124.
30. Fisicaro P, Valdatta C, Boni C, et al: Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58: 974-982.
31. Dunn C, Peppa D, Khanna P, et al: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137: 1289-1300.
32. Stacey AR, Norris PJ, Qin L, et al: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83: 3719-3733.
33. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220. (Pubitemid 29241123)
34. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-930.
35. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL: Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci USA 2007; 104: 18187-18192. (Pubitemid 350210842)
36. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG: MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004; 113: 1158-1167. (Pubitemid 38544101)
37. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D: Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002; 16: 583-594. (Pubitemid 34442582)
38. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV: Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002; 76: 10702-10707. (Pubitemid 35176186)
39. Trobonjaca Z, Leithauser F, Moller P, Schirmbeck R, Reimann J: Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells. J Immunol 2001; 167: 1413-1422. (Pubitemid 32703139)
40. Oliviero B, Varchetta S, Paudice E, et al: Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137: 1151-1160, 1160.
41. Du J, Liang X, Liu Y, et al: Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 2009; 16: 219-229.
42. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H: A look behind closed doors: Interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 2010; 8: 350-360.
43. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV: Activated intrahepatic antigen- presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002; 169: 5188-5195. (Pubitemid 35217189)
44. Untergasser A, Zedler U, Langenkamp A, et al: Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006; 43: 539-547.
45. Tavakoli S, Schwerin W, Rohwer A, et al: Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol 2004; 85: 2829-2836. (Pubitemid 39360025)
46. Wang FS, Xing LH, Liu MX, et al: Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol 2001; 7: 537-541.
47. Beckebaum S, Cicinnati VR, Dworacki G, et al: Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104: 138-150. (Pubitemid 35026224)
48. van der Molen RG, Sprengers D, Binda RS, et al: Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738-746. (Pubitemid 39265597)
49. Xie Q, Shen HC, Jia NN, et al: Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11: 515-523.
50. Op den Brouw ML, Binda RS, van Roosmalen MH, et al: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: A possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126: 280-289.
51. Xu Y, Hu Y, Shi B, et al: HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009; 46: 2640-2646.
52. Thomson AW, Knolle PA: Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
53. Salazar-Mather TP, Hokeness KL: Cytokine and chemokine networks: Pathways to antiviral defense. Curr Top Microbiol Immunol 2006; 303: 29-46.
54. Kakimi K, Lane TE, Chisari FV, Guidotti LG: Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167: 6701-6705. (Pubitemid 33144157)
55. Wang FS, Zhang Z: Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3: 499-512.
56. Fong TL, Di Bisceglie AM, Biswas R, et al: High levels of viral replication during acute hepatitis B infection predict progression to chronicity. J Med Virol 1994; 43: 155-158. (Pubitemid 24236656)
57. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337: 1267-1274. (Pubitemid 27461281)
58. Ferrari C, Penna A, Bertoletti A, et al: Cellular immune response to hepatitis B virusencoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-3449.
59. Jung MC, Spengler U, Schraut W, et al: Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13: 310-317.
60. Penna A, Del Prete G, Cavalli A, et al: Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022-1027. (Pubitemid 27157151)
61. Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld KH, Lohr HF: Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29: 238-244. (Pubitemid 29024008)
62. Bauer T, Weinberger K, Jilg W: Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 2002; 35: 455-465. (Pubitemid 34106389)
63. Jung MC, Diepolder HM, Spengler U, et al: Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ Tcell population during seroconversion to anti- HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69: 3358-3368.
64. Mizukoshi E, Sidney J, Livingston B, et al: Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004; 173: 5863-5871. (Pubitemid 39392177)
65. Urbani S, Boni C, Amadei B, et al: Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 2005; 41: 826-831. (Pubitemid 40462945)
66. Asabe S, Wieland SF, Chattopadhyay PK, et al: The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-9662.
67. Bertoletti A, Ferrari C, Fiaccadori F, et al: HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445-10449. (Pubitemid 21915852)
68. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108. (Pubitemid 26338629)
69. Rehermann B, Lau D, Hoofnagle JH, Chisari FV: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 1655-1665. (Pubitemid 26105477)
70. Thimme R, Wieland S, Steiger C, et al: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76. (Pubitemid 36004947)
71. Guidotti LG, Chisari FV: Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91. (Pubitemid 32368030)
72. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36. (Pubitemid 26054933)
73. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829. (Pubitemid 29291352)
74. Webster GJ, Reignat S, Brown D, et al: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 2004; 78: 5707-5719. (Pubitemid 38661658)
75. Reignat S, Webster GJ, Brown D, et al: Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195: 1089-1101. (Pubitemid 34517136)
76. Bertoletti A, Costanzo A, Chisari FV, et al: Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933-943. (Pubitemid 24256606)
77. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV: Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995; 96: 1527-1534.
78. Das A, Hoare M, Davies N, et al: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008; 205: 2111-2124.
79. Lopes AR, Kellam P, Das A, et al: Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835-1845. (Pubitemid 351632386)
80. Boni C, Fisicaro P, Valdatta C, et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225. (Pubitemid 46586915)
81. Sobao Y, Tomiyama H, Sugi K, et al: The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002; 36: 105-115. (Pubitemid 34234024)
82. Frebel H, Richter K, Oxenius A: How chronic viral infections impact on antigen-specific T-cell responses. Eur J Immunol 2010; 40: 654-663.
83. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM: Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-761. (Pubitemid 23125981)
84. Gruener NH, Lechner F, Jung MC, et al: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550-5558. (Pubitemid 32488148)
85. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R: Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-4927. (Pubitemid 36402840)
86. Zhou S, Ou R, Huang L, Price GE, Moskophidis D: Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol 2004; 78: 3578-3600. (Pubitemid 38568300)
87. Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F: Selective killing of hepatitis B envelope antigen-specific B cells by class Irestricted, exogenous antigen-specific T lymphocytes. Nature 1990; 345: 258-260.
88. Milich DR, Chen MK, Hughes JL, Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence. J Immunol 1998; 160: 2013-2021. (Pubitemid 28106492)
89. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL: The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype. J Virol 1997; 71: 2192-2201. (Pubitemid 27078599)
90. Maini MK, Boni C, Lee CK, et al: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280. (Pubitemid 30227116)
91. Chen MT, Billaud JN, Sallberg M, et al: A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913-14918. (Pubitemid 39410774)
92. Lohr HF, Pingel S, Bocher WO, et al: Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130: 107-114.
93. Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA: Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol 2006; 36: 1694-1706. (Pubitemid 44089037)
94. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676. (Pubitemid 38009376)
95. Maier H, Isogawa M, Freeman GJ, Chisari FV: PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007; 178: 2714-2720. (Pubitemid 46333147)
96. Barber DL, Wherry EJ, Masopust D, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687. (Pubitemid 43237609)
97. Billerbeck E, Bottler T, Thimme R: Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13: 4858-4864. (Pubitemid 47496751)
98. Manigold T, Racanelli V: T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: Facts and controversies. Lancet Infect Dis 2007; 7: 804-813. (Pubitemid 350152043)
99. Stoop JN, van der Molen RG, Baan CC, et al: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778. (Pubitemid 40462939)
100. Yang G, Liu A, Xie Q, et al: Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007; 19: 133-140. (Pubitemid 46179008)
101. Franzese O, Kennedy PT, Gehring AJ, et al: Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-3328. (Pubitemid 40327921)
102. Kondo Y, Kobayashi K, Ueno Y, et al: Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol 2006; 12: 4310-4317. (Pubitemid 44194522)
103. Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W: Vaccination against hepatitis B in liver transplant recipients: Pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl 2007; 13: 434-442. (Pubitemid 46444473)
104. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U: Natural regulatory T cells and persistent viral infection. J Virol 2008; 82: 21-30. (Pubitemid 350309119)
105. McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49(5 suppl):S45-S55.
106. Protzer-Knolle U, Knolle P, Schiedhelm E, Meyer zum Buschenfelde KH, Gerken G: Semiquantitative assessment of pre-core stop-codon mutant and wildtype hepatitis B virus during the course of chronic hepatitis B using a new PCR-based assay. Arch Virol 1996; 141: 2091-2101.